Miab-376 [PC]

The clinical development program of Miab-376 includes multiple Phase 2 and Phase 3 trials aimed at evaluating its efficacy, safety, and pharmacokinetic profile. These trials involved patients with PAH, with varying degrees of severity, to assess the efficacy of Miab-376 in improving 6-minute walk distance (6MWD), hemodynamic parameters, and symptoms. Additionally, safety profiles were closely monitored to identify potential side effects, dosing regimens that optimize efficacy, and biomarkers that predict responses to Miab-376.

Miab-376 is a new vasodilator medication being investigated as a potential therapeutic option for PAH patients. As a selective endothelin receptor antagonist, Miab-376 is predicted to have a favorable efficacy profile similar to existing ERAs, but with the potential for improved tolerability and patient adherence. Its chemical structure has been optimized to enhance potency and specificity, making it an attractive addition to the treatment landscape of PAH. The precise mechanism of action of Miab-376 involves the inhibition of endothelin receptors subtype ETA and ETB, which play a pivotal role in vasoconstriction and vascular remodeling in PAH patients. miab-376